Showing 5051-5060 of 20470 results for "".
- Aesthetic Sequelae of GLP-1 Receptor Agonists Highlighted in Clinical Reviewhttps://reachmd.com/news/aesthetic-sequelae-of-glp-1-receptor-agonists-highlighted-in-clinical-review/2485615/Dermatologists are increasingly encountering aesthetic complications associated with GLP-1 receptor agonist (RA)–induced weight loss, according to a clinical review presented at the South Beach Symposium. The poster, b
- Prolactin Receptor Blockade May Promote Hair Growth via Follicular Stem Cell Activationhttps://reachmd.com/news/prolactin-receptor-blockade-may-promote-hair-growth-via-follicular-stem-cell-activation/2485612/Blocking prolactin receptor (PRLR) signaling with the investigational antibody ABS-201 promoted hair follicle growth and stem cell activation in human male scalp skin models, according to preclinical data from Jérémy Chéret, PhD, MSc, at the South Beach Symposium
- Micro-Autologous Fat Transplantation Shows Durable Correction for Gummy Smile in Long-Term Studyhttps://reachmd.com/news/micro-autologous-fat-transplantation-shows-durable-correction-for-gummy-smile-in-long-term-study/2485602/Micro-autologous fat transplantation (MAFT) may offer a durable, minimally invasive option for correcting gummy smile, according to a long-term retrospective study published online ahead of print in Plastic and Reconstructive Surgery. Investigators analyzed outcomes in 52 patients
- 2024-2025 COVID-19 Vaccine Effectiveness Against Hospitalization and Severe Outcomeshttps://reachmd.com/news/covid-19-vaccine-effectiveness-hospitalization-severe-outcomes/2485600/A multicenter test-negative, case-control analysis conducted by the IVY Network evaluated the effectiveness of the 2024–2025
- FDA Accepts Galderma’s RelabotulinumtoxinA BLA Resubmissionhttps://reachmd.com/news/fda-accepts-galdermas-relabotulinumtoxina-bla-resubmission/2485601/Galderma announced that the US Food and Drug Administration (FDA) has accepted the resubmitted Biologics License Application (BLA) for relabotulinumtoxinA (Relfydess™) for the temporary improvement of moderate-to-severe glabellar lines and lateral canthal lines in a
- New Consensus Algorithm Guides Skincare Use With Energy-Based Acne Treatmentshttps://reachmd.com/news/new-consensus-algorithm-guides-skincare-use-with-energy-based-acne-treatments/2485595/A new consensus-based study published in Journal of Drugs in Dermatology outlines a practical, stepwise algorithm for integrating skincare with energy-based devices (EBDs) in the management of acne and acne sequelae. Titled “Practical Algorithm for Acne Treatment Integrating Skincare
- How Obesity Genetics Shape Multimorbidityhttps://reachmd.com/news/obesity-genetics-multimorbidity-gemini/2485583/The GEMINI study used a genetics-informed, pairwise multimorbidity framework to examine why long-term conditions co-occur. Across approximatel
- Validating the Arabic MOS Pain Effects Scale for Adults With MShttps://reachmd.com/news/arabic-mos-pain-scale-ms/2485590/PES-Ar, the Arabic version of the 6-item MOS Pain Effects Scale, has been validated for adults with multiple sclerosis in Saudi Arabia, showing strong test–retest reliabi
- Computational Network Study Highlights CD44 as a Potential MS Targethttps://reachmd.com/news/cd44-potential-ms-target/2485589/A new computational study is drawing attention to CD44, a cell-surface receptor long associated with immune cell trafficking, as a potentially important therapeutic target in multiple sclerosis.
- Analysis: ChatGPT and DeepSeek Largely Align With Psoriasis Treatment Guidelineshttps://reachmd.com/news/analysis-chatgpt-and-deepseek-largely-align-with-psoriasis-treatment-guidelines/2485578/Large language models (LLMs) ChatGPT and DeepSeek generally adhere to established psoriasis treatment guidelines, but some performance gaps remain. Investigators publishing in the Journal of Drugs in Dermatology exp